Department of Oral and Maxillofacial Surgery and Pharmacology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Oral and Maxillofacial Surgery, NYU Langone Hospitals, New York, NY, USA.
J Dent Res. 2023 Mar;102(3):313-321. doi: 10.1177/00220345221133716. Epub 2022 Nov 8.
Repair and functional reconstruction of large jawbone defects remain one of the challenges in the field of head and neck surgery. The recent progress in tissue engineering technologies and stem cell biology has significantly promoted the development of regenerative reconstruction of jawbone defects. The multiple trophic activities of extracellular vesicles (EVs) produced by mesenchymal stem cells (MSCs) may play a critical role in their therapeutic effects. Accumulating evidence has shown the promise of dental pulp stem cells (DPSCs) in bone regeneration, but less is known about the regenerative effects of DPSC-EVs on jawbone defects. The purpose of this study is to explore the osteogenic effects of DPSC-EVs on jawbone marrow-derived MSCs (JB-MSCs) in vitro and their osteoinductive effects in a mandibular bone defect model in rats. Our results showed that JB-MSCs could efficiently uptake DPSC-EVs, which in turn significantly promoted the expression of osteogenic genes, such as runt-related transcription factor 2 (), alkaline phosphatase (), and osteocalcin (), as well as the osteogenic differentiation capability of JB-MSCs. Meanwhile, we found that the pro-osteogenic effect in vitro induced by DPSC-EVs was comparable to that induced by BMP-2 (bone morphogenetic protein 2), currently the only Food and Drug Administration-approved osteoinductive growth factor. In vivo, animals that were locally treated with DPSC-EVs laden with a commercially available collagen membrane exhibited a relatively fast wound closure and increased new bone density at the mandible defects. Our results provide evidence for the osteogenic and osteoinductive effects of DPSC-EVs on jawbone regeneration. Due to the accessibility, rapid proliferation, and osteogenic propensity of DPSCs, DPSC-EVs may represent a safe cell-free therapeutic approach for craniofacial bone regeneration.
修复和功能性重建大的颌骨缺损仍然是头颈部外科领域的挑战之一。组织工程技术和干细胞生物学的最新进展极大地促进了颌骨缺损的再生重建。间充质干细胞(MSCs)产生的细胞外囊泡(EVs)的多种营养活性可能在其治疗效果中起关键作用。越来越多的证据表明牙髓干细胞(DPSCs)在骨再生中的潜力,但关于 DPSC-EVs 对颌骨缺损的再生作用知之甚少。本研究旨在探讨 DPSC-EVs 对体外颌骨髓源性间充质干细胞(JB-MSCs)的成骨作用及其在大鼠下颌骨缺损模型中的成骨作用。我们的结果表明,JB-MSCs 可以有效地摄取 DPSC-EVs,这反过来又显著促进了成骨基因如 runt 相关转录因子 2()、碱性磷酸酶()和骨钙素()的表达,以及 JB-MSCs 的成骨分化能力。同时,我们发现 DPSC-EVs 在体外诱导的促成骨作用与目前唯一获得美国食品和药物管理局批准的成骨诱导生长因子 BMP-2(骨形态发生蛋白 2)相当。在体内,局部用商业上可获得的胶原膜负载 DPSC-EVs 的动物表现出相对较快的伤口闭合和下颌骨缺损处新骨密度增加。我们的结果为 DPSC-EVs 对颌骨再生的成骨和成骨诱导作用提供了证据。由于 DPSCs 的可及性、快速增殖和成骨倾向,DPSC-EVs 可能代表一种安全的无细胞治疗方法,用于颅面骨再生。
J Dent Res. 2023-3
Acta Biomater. 2020-6
Stem Cell Res Ther. 2018-2-1
Biomolecules. 2025-6-30
Int J Oral Sci. 2025-6-16
Naunyn Schmiedebergs Arch Pharmacol. 2025-6-10
Stem Cell Res Ther. 2025-4-17